Evidence map›Paper›PMID 41136574›Full record

Observational studyEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2025

Patterns of lymph node recurrence in sinonasal cancers: risk factors and oncological outcomes.

Gianluca Dalfino, Giorgio Sileo, Alessia Lambertoni, Alberto Daniele Arosio, Giulia Monti, Marco Valentini, Mario Turri Zanoni, Maurizio Bignami

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Gianluca DalfinoDivision of Otorhinolaryngology Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9 -, 21100, Varese, Italy. gianluca.dalfino@gmail.com.ORCID http://orcid.org/0000-0002-1380-4206
Giorgio SileoDivision of Otorhinolaryngology Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9 -, 21100, Varese, Italy.
Alessia LambertoniDivision of Otorhinolaryngology Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9 -, 21100, Varese, Italy.
Alberto Daniele ArosioDivision of Otorhinolaryngology Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9 -, 21100, Varese, Italy.
Giulia MontiDivision of Otorhinolaryngology Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9 -, 21100, Varese, Italy.
Marco ValentiniDivision of Otorhinolaryngology Head and Neck Surgery, University of Insubria, Como, Italy.
Mario Turri ZanoniDivision of Otorhinolaryngology Head and Neck Surgery, University of Insubria, Como, Italy.
Maurizio BignamiDivision of Otorhinolaryngology Head and Neck Surgery, Department of Biotechnology and Life Sciences, University of Insubria, Via Guicciardini, 9 -, 21100, Varese, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSinonasal tumors are rare and heterogeneous diseases with a low incidence of neck node metastasis. This study aims to analyze the risk of neck nodes recurrences and to assess patterns and predictors of nodal recurrence in sinonasal malignancies.

methodsRetrospective observational cohort study on 574 patients affected by sinonasal malignant tumor who were treated via endoscopic-assisted approaches between January 1998 and December 2023 in our tertiary-care referral University hospital. Nodal recurrence-free survival (N-RFS) was analyzed using Kaplan-Meier curves, with univariate and multivariate Cox regression identifying prognostic factors.

resultsNodal involvement at diagnosis was observed in 3.1% (18/574) of patients. During a median follow-up of 62.9 months, nodal recurrence occurred in 6.8% (39/574). Histologies with the highest recurrence included sinonasal neuroendocrine carcinoma (23.5%), sinonasal undifferentiated carcinoma (18.8%), and olfactory neuroblastoma (12.8%). Univariate analysis revealed pT classification (pT > 3), tumor grading (G3/G4), and surgical approach as significant predictors of nodal recurrence. In multivariate analysis, high-grade tumors (HR = 3.109, p = 0.003) and craniofacial/cranio-endoscopic approaches (HR = 2.495, p = 0.023) remained independently associated with worse N-RFS.

conclusionsHistotype is the most important factor in determining the incidence and pattern of regional recurrence. Both high tumor grade and more extensive surgical procedures are independent predictors of regional failure. Therefore, long-term follow-up is essential, especially for specific histologies such as olfactory neuroblastoma and sinonasal neuroendocrine carcinoma. Elective neck treatment should be personalized, taking into account the tumor's histology, grading and overall disease extent to optimize patient outcomes.

Indexed as

CarcinomaCarcinoma, NeuroendocrineEsthesioneuroblastoma, OlfactoryLymph NodesNeoplasm Recurrence, LocalParanasal Sinus NeoplasmsAdultAgedAged, 80 and overEndoscopyFemaleHumansLymphatic MetastasisMaleMiddle AgedNeoplasm StagingLymph node recurrenceRecurrence risk factorsRegional recurrenceSinonasal malignant tumorsSurvival recurrence

Identifiers

PMID41136574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.